Immunity
Conditions
Keywords
Nokyong
Brief summary
This study was conducted to investigate the efficacy and Safety of Nokyong Mixture Extract(CME-PI) on Promotion of Immunity
Detailed description
This study was a 8 weeks, randomized, double-blind, placebo-controlled human trial. 80 subjects were randomly divided into Nokyong Mixture Extract(CME-PI) group or placebo group. The investigators measured Natural Killer cell activity, Cytokines(IL-2, IL-12, IFN-γ, TNF-α), questionnaire scores of upper airway infection.
Interventions
DIETARY_SUPPLEMENTNokyong Mixture Extract(CME-PI)
2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
DIETARY_SUPPLEMENTPlacebo
Placebo for 8 week
Sponsors
Chonbuk National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Adult men and women over 50 years * After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice
Exclusion criteria
* If screening shows that the white blood cell(WBC) is less than 3000/㎕ or more than 8000/㎕ * Those who received influenza vaccination within 3 months before the screening * Those who have a body mass index(BMI) of less than 18.5 kg / m\^2 or greater than 35 kg / m\^2 at the screening * Those who have a clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, liver biliary system, kidney and urinary system, neuropsychiatry, musculoskeletal system, inflammatory and hematologic * Those who take a medication or health function food that affects your promotion of immunity within 1 month prior to the screening * Those who have received antipsychotic medication within 3 months before screening * Those who alcoholic or drug abuse suspected * Those who participated in other clinical trials within 3 months before screening * Laboratory test by show the following results * Aspartate Transaminase(AST), Alanine Transaminase(ALT) \> Reference range 3 times upper limit * Serum Creatinine \> 2.0 mg/dL * Pregnancy or breast feeding * Those who doesn't accept the implementation of appropriate contraception of a childbearing woman * Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of Natural Killer cell activity | 8 weeks | Natural Killer cell activity was measured in study baseline and 8 week. A ratio of effector cell and target cell was 50:1, 25:1, 12.5:1. (Experimental - Effector Spontaneous - Target Spontaneous) / (Target Maximum - Target Spontaneous) × 100 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of Cytokines | 8 weeks | For blood Cytokines analysis, collect 3 ml of blood in one SST tube for 5 ml, leave at room temperature for 30 minutes for clotting, after then centrifuge at 3000 rpm (or 2000 xg) for 10 minutes. Inspection item were IL-2, IL-6, IL-12, IFN-γ, TNF-α. |
| Changes of Upper respiratory infection questionnaire score | 8 weeks | The upper respiratory infection questionnaire will investigate the occurrence of symptoms of upper respiratory infections (or symptoms), the score by symptom, the duration (days), and survey on the day of visit (1st, 2nd and 3rd visits). The questionnaire items were classified into three groups according to whether or not the symptoms of upper respiratory infections (or symptoms) occurrence (yes or no), the types of symptoms (sore throat, rhinorrhea, nasal obstruction, sneezing, hoarseness, myalgia, earache, fever, headache, cough, sputum, dyspnea, diarrhea, nausea, vomiting)and symptoms level (0 if no symptoms, 1 if slightly, 2 if normal, 3 severe). |
Countries
South Korea
Outcome results
None listed